Belviq (Lorcaserin) Cancer Lawsuit Investigation
Belviq weight loss drug pulled from shelves after FDA says study shows increase in cancer
On February 13, 2020, weight loss drugs Belviq and Belviq XR (lorcaserin) were withdrawn at the FDA’s request after a clinical trial showed an increased incidence of cancer in people who used the drugs.
If you’ve taken Belviq and have been diagnosed with colorectal, pancreatic, or lung cancer, our personal injury attorneys are interested in speaking with you.
Diagnosed with cancer after taking Belviq?
You may be entitled to compensation. Get a free and confidential consultation.
FDA requests withdrawal of Belviq after study shows increase in cancer
On February 13, 2020, Eisai Co. withdrew its weight loss drugs Belviq and Belviq XR at the Federal Drug Administration’s request, after a clinical trial showed an increased incidence of cancer in people who used the drugs.
The FDA first alerted the public that results showed a possible increased risk of cancer on January 14, 2020.
In its follow-up February 13 safety communication, the FDA said:
We are taking this action because we believe that the risks of lorcaserin outweigh its benefits.
No new study prompted this withdrawal; instead, it was the FDA’s completed review of data from a clinical trial for lorcaserin that was conducted from 2013 to 2018. This trial was initially focused on evaluating lorcaserin’s risk of cardiovascular problems, rather than cancer.
The FDA explains that for the first few months of the trial, there was “no apparent difference” in the incidence of cancer between the group that took lorcaserin and the group that didn’t; but the longer the trial went on, the more frequently cancer occurred for the lorcaserin group.
While the FDA says a range of cancer types occurred, it identified the most frequent types as:
- pancreatic
- colorectal
- lung
Our Personal Injury Lawyers
Eric Gibbs
A founding partner at the firm, Eric has negotiated groundbreaking settlements that favorably shaped laws and resulted in business practice reforms.
View full profileKaren Menzies
Karen has extensive experience in federal and state mass tort litigation. She has been appointed by the courts to serve in many leadership positions.
View full profileAmy Zeman
Amy has built a reputation in the plaintiffs’ bar for delivering results to consumers and sexual assault survivors in class actions and mass torts.
View full profileAndre Mura
Andre represents plaintiffs in class actions and mass torts, including in the areas of consumer protection, privacy, and products liability.
View full profileAbout Us
